Success Story: NIW Approved Without RFE! We Helped a Cancer Neuroscience Researcher From China Achieve Success under Premium Processing

Client’s Testimonial:

 

"Thank you for the great news. It has been a pleasure working with your firm, and I truly appreciate your help throughout my NIW petition process."

 


 

On May 14th, 2026, we received another EB-2 NIW (National Interest Waiver) approval for an Expert in the Field of Cancer Neuroscience (Approval Notice).

 


 

General Field: Cancer Neuroscience

 

Country of Origin: China

 

State of Residence at the Time of Filing: Pennsylvania

 

Approval Notice Date: May 14th, 2026

 

Processing Time: 1 month, 12 days (Premium Processing Requested)

 


 

Case Summary:

 

This approval is yet another testament to our firm's commitment to building strong, well-supported petitions for talented researchers worldwide. We are pleased to share the success of an EB-2 NIW (National Interest Waiver) petition for a researcher in cancer neuroscience from China. Holding an M.S. in biology, this researcher secured approval by demonstrating that their work possesses both substantial merit and national importance to the United States.

 

Demonstrating Influence Through Research Impact

 

To demonstrate that this researcher is well-positioned to advance the proposed endeavor, our firm presented a documented record of scholarly success. The portfolio includes 4 peer-reviewed journal articles, with publications appearing in some of the most prestigious venues in the field. The work has been cited 33 times.

 

Funding support from the National Institutes of Health (NIH) and the Dr. Miriam & Sheldon G. Adelson Medical Research Foundation, organizations that reserve support exclusively for research advancing the national interest in health and disease, served as meaningful external validation of the work's significance and real-world impact.

 

The Result

 

With our firm's strategic preparation and careful framing of the petition, approval was granted in just over 1 month under premium processing without RFE. This outcome reflects both the strength of the researcher's contributions and our team's expertise in presenting complex scientific work in the most compelling light. We are proud to have supported this dedicated cancer neuroscience researcher and extend our sincere best wishes for continued success in the United States.